Overview

A Study to Evaluate Safety and Tolerability of Single Ascending Doses of Rozanolixizumab Administered by Subcutaneous Infusion in Healthy Japanese, Chinese and Caucasian Study Participants

Status:
Completed

Trial end date:
2020-04-28

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of rozanolixizumab in japanese, chinese and caucasian healthy-volunteer study participants.

Phase:

Phase 1

Details

Lead Sponsor:

UCB Biopharma S.P.R.L.

Treatments:

Rozanolixizumab